News

Ask the Doctor: What is the current efficacy of oral therapies for marginal zone lymphoma?

There are several chemotherapy and targeted anticancer drugs approved or under investigation for the treatment of lymphoma. Unlike traditional chemotherapy that is administered intravenously (IV) in a hospital or clinic, oral therapies are administered via a pill, taken at home…

Lymphoma Research Foundation Funds 29 New Grants Investigating Lymphoma and Chronic Lymphocytic Leukemia, Introduces Expanded Research Program and Health Equity Initiative

Investment supports early-career scientists dedicated to developing patient therapies and lymphoma cures.

Lymphoma Research Foundation Unites Lymphoma Community Nationwide Through Lymphoma Walk Program, Walk On! America

Thousands to Raise Awareness and Funds through Virtual Celebration and Socially Distanced Neighborhood Walks The Lymphoma Research Foundation (LRF) will offer Walk On! America, a twist on its Spring 2021 Team LRF Lymphoma Walks to bring the lymphoma community together safely in the time of COVID-19. Lymphoma…

U.S. Food and Drug Administration Approves CAR T Cell Therapy for Follicular Lymphoma

Axicabtagene ciloeucel has been approved for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).

Best Shot: A Story of Hope

When Chris Gorelik received news that his central nervous system lymphoma would leave him with months to live, he sought a second opinion and took a chance on a new treatment protocol — to give him a fighting chance to see his children grow up.

The Ripple Effect in Lymphoma Research

LRF Scientific Advisory Board (SAB) member and grantee Michael Williams, MD, of the University of Virginia School of Medicine, sees lymphoma research as having a ripple effect. A lymphoma researcher has a much larger impact on the lives of those touched by this disease.

Updates from the 2020 American Society of Hematology Annual Meeting

Widely regarded as the premier event in malignant and non-malignant hematology, the ASH Meeting provided a critical forum for leading hematologists/ oncologists to present their findings to over 20,000 of their peers.

ASH 2020: Retrospective Study Reveals Transplant Potentially Curative for Mature T-cell Lymphoma

Allogeneic hematopoietic stem cell transplant (allo-HSCT) may be a successful curative treatment for T-cell patients with poor survival and/or limited treatment options, according to a retrospective study led by LRF grantee Neha Mehta-Shah, MD of the Washington University School of Medicine in St. Louis.

ASH 2020: Transplant Increases Overall Survival in Older, High-Risk Patients with Myelodysplastic Syndromes

Myelodysplastic Syndromes (MDS), also known as “bone marrow failure disorder,” are a group of diverse bone marrow disorders in which the bone marrow does not produce enough healthy blood cells.

ASH 2020: BTK Inhibitor Shows Promise in Previously Treated Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma and other Non-Hodgkin Lymphomas

Researchers in BRUIN trial reveals promising data on BTK inhibitor in treatment for CLL, MCL and WM

Subscribe to Our Emails. Get lymphoma and CLL resources and updates.